

Table.

	Response	AE
	Odds Ratio (95% CI)	
BTKi		
Zanubrutinib	Reference	Reference
Ibrutinib	0.75 (0.38, 1.47)	1.17 (0.61, 2.24)
Acalabrutinib	0.87 (0.45, 1.69)	1.52 (0.80, 2.87)
Age	0.54 (0.31, 0.96)*	2.52 (1.43, 4.47)*
Gender		
Male	Reference	Reference
Female	0.91 (0.84, 0.98)*	0.96 (0.92, 1.01)
RACE		
White	Reference	Reference
Non-White	1.11 (0.63, 1.94)	1.44 (0.84, 2.46)
Ann Arbor stage		
2+	Reference	Reference
0/1	1.04 (0.57, 1.91)	0.70 (0.40, 1.22)
ECOG		
2+	Reference	Reference
0/1	0.31 (0.07, 1.43)	0.69 (0.27, 1.72)
Splenic involvement		
Yes	Reference	Reference
No	0.34 (0.19, 0.60)*	0.49 (0.28, 0.86)*
Extranodal disease involvement		
Yes	Reference	Reference
No	0.33 (0.16, 0.68)*	0.31 (0.14, 0.68)*
BTKi line of therapy		
2L+	Reference	Reference
1L	0.73 (0.25, 2.16)	0.26 (0.01, 0.70)*

*P value <0.05